Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier

Journal of Controlled Release

Volumn 46, Issue 1-2, 1997, Pages 117-128

  Friden, Phillip M ^a,b  

^a ALKERMES INC   (United States)

^b Periodontix Inc   (United States)

Author keywords

Antibody conjugate; Blood brain barrier; Drug delivery; Neurotrophic factors; Transferrin receptor

Indexed keywords

ANTIBODY CONJUGATE; NERVE GROWTH FACTOR; PEPTIDES AND PROTEINS; TRANSFERRIN RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

BLOOD BRAIN BARRIER; BRAIN TISSUE; CAPILLARY ENDOTHELIUM; CELL TRANSPORT; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; PRIORITY JOURNAL; TRANSCYTOSIS;

EID: 0031054009     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(96)01580-5     Document Type: Conference Paper

References (45)

1. W.M. Pardridge, Peptide Drug Delivery to the Brain, Raven Press, New York, 1991.
2. S.I. Rapoport, Osmotic opening of the blood-brain barrier, Ann. Neurol. 24 (1988) 677-680.
3. N.H. Greig, W.R. Fredericks, H.W. Holloway, T.T. Soncrant and S.I. Rapoport, Delivery of human interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat, J. Pharmacol. Exp. Ther. 245 (1988) 581-586.
4. T.S. Salahuddin, B.B. Johansson, H. Kalimo and Y. Olsson, Structural changes in the rat brain after intracarotid infusions of hyperosmolar solutions: an electron microscopic study, Acta Neuropathol. 77 (1988) 5-13.
5. E.M. Heisiger, R.M. Voorhies, G.A. Basler, L.E. Lipschutz, J.B. Posner and W.R. Shapiro, Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow, Ann. Neurol. 19 (1986) 50-59.
6. 14C methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study, Cancer Res. 48 (1988) 694-701.
7. E.A. Neuwelt, J. Howieson, E.P. Frankel, H.D. Specht, R. Weigel, C.G. Buchan and S.A. Hill, Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma, Neurosurgery 19 (1986) 573-582.
8. T. Inamura, T. Nomura, R.T. Bartus and K.L. Black, Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors, J. Neurosurg. 81 (1994) 752-758.
9. E. Sanovich, R.T. Bartus, P.M. Friden, R.L. Dean, H.Q. Le and M.W. Brightman, Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7, Brain Res. 705 (1995) 125-135.
10. N. Bodor, L. Prokai, W-M. Wu, H. Farag, S. Jonalagadda, M. Kawamura and J. Simpkins, A strategy for delivering peptides into the central nervous system by sequential metabolism, Science 257 (1992) 1698-1700.
11. Houthoff, H.J., Mortz, R.V., Rennke, H.G. and H.M. Wisniewski, The role of molecular charge in the extravasation and clearance of protein tracers blood-brain barrier impairment and cerebral edema, in: K.G. Go and A. Baethmann (Eds.), Recent Progress in the Study and Therapy of Brain Edema, Plenum Publishing Corp., New York, 1984, pp. 67-79.
12. D. Triguero, J.B. Buciak, J. Yang and W.M. Pardridge, Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein, Proc. Natl. Acad. Sci. USA 86 (1989) 4761-4765.
13. W.M. Pardridge, D. Triguero, J. Buciak and J. Yang, Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector, J. Pharmacol. Exp. Ther. 255 (1990) 893-899.
14. A. Muckerheide, R.J. Apple, A.J. Pesce and J.G. Michael, Cationization of protein antigens; I: alteration of immunogenic properties, J. Immunol. 138 (1987) 833-837.
15. W.M. Pardridge, Brain metabolism: a perspective from the blood-brain barrier, Physiol. Rev. 63 (1983) 1481-1535.
16. P.M. Friden, Receptor-mediated transport of peptides and proteins across the blood-brain barrier, in: W.M. Pardridge (Ed.), The Blood-Brain Barrier: Cellular and Molecular Biology, Raven Press, NY, 1993, pp. 229-248.
17. J.B. Fishman, J.B. Rubin, J.V. Handrahan, J.R. Connor and R.E. Fine, Receptor-mediated trancytosis of transferrin across the blood-brain barrier, J. Neurosci. Res. 18 (1987) 299-304.
18. E.M. Taylor, A. Crowe and E.H. Morgan, Transferrin and iron uptake by the brain: effects of altered iron status, J. Neurochem. 57 (1991) 1584-1592.
19. S-U. Shin, P. Friden, M. Moran, T. Olson, Y-S. Kang, W.M. Pardridge and S.L. Morrison, Transferrin-antibody fusion proteins are effective in brain targeting, Proc. Natl. Acad. Sci. USA 92 (1995) 2820-2824.
20. W.A. Jefferies, M.R. Brandon, S.Y. Hunt, A.F. Williams, K.C. Gatter and D.Y. Mason, Transferrin receptor on endothelium of brain capillaries, Nature 312 (1984) 162-163.
21. P.M. Friden, L.R. Walus, G.F. Musso, M.A. Taylor, B. Malfroy and R.M. Starzyk, Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier, Proc. Natl. Acad. Sci. USA 88 (1991) 4771-4775.
22. P.M. Friden, L.R. Walus, P. Watson, S.R. Doctrow, J.W. Kozarich, C. Backman, H. Bergman, B. Hoffer, F. Bloom and A-C. Granholm, Blood-brain barrier penetration and in vivo activity of an NGF conjugate, Science 259 (1993) 373-377.
23. R.D. Broadwell, B.J. Balin and M. Salcman, Transcytotic Pathway for Blood-Borne Protein Through the Blood-Brain Barrier, Proc. Natl. Acad. Sci. USA 85 (1988) 632-636.
24. R.D. Broadwell, B.J. Baker, W.A. Banks, P. Friden, M. Moran, C. Oliver and J.C. Villegas, Ferrotransferrin and antibody against the transferrin receptor as potential vehicles for drug delivery across the mammalian blood-brain barrier into the central nervous system, in: T.R. Flanagan, D.F. Emerich and S.R. Winn (Eds.), Methods in Neuroscience, Vol. 21; Providing Pharmaceutical Access to the Brain: Alternative Approaches, Academic Press, San Diego, CA, 1994.
25. U. Bickel, Y-S. Kang, T. Yoshikawa and W.M. Pardridge, In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium, J. Histochem. Cytochem. 42 (1994) 1493-1497.
26. R. Levi-Montalcini, The nerve growth factor 35 years later, Science 237 (1987) 1154-1162.
27. F. Hefti, Nerve growth factor (NGF) promotes survival of septal cholinergic neurons after fimbrial transections, J. Neurosci. 6 (1986) 2155-2162.
28. M.B. Rosenberg, T. Friedmann, R.C. Robertson, M. Tuszynski, J.A. Wolff, X.O. Breakfield and F.H. Gage, Grafting genetically modified cells to the damaged brain: Restorative effects of NGF expression, Science 242 (1988) 1575-1578.
29. F. Hefti, J. Hartikka and B. Knusel, Function of neurotrophic factors in the adult and aging brain and their possible use in treatment of neurodegenerative diseases, Neurobiol. Aging 10 (1989) 515-533.
30. B.N. Saffran, Should intracerebroventricular nerve growth factor be used to treat Alzheimer's disease? Perspect. Biol. Med. 35 (1992) 471-486.
31. 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report), J. Neural. Transm. 4 (1992) 79-95.
32. A-C. Granholm, C. Backman, F. Bloom, T. Ebendal, G. Gerhardt, B. Hoffer, L. Mackerlova, L. Olson, S. Soderstrom, L.R. Walus and P.M. Friden, NGF and anti-transferrin receptor antibody conjugate: short and long term effects on survival of cholinergic neurons in intraocular septal transplants, J. Pharmacol. Exp. Ther. 268 (1994) 448-459.
33. J.F. Poduslo and G.L. Curran, Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers, Mol. Brain Res. 23 (1994) 157-162.
34. L. Olson, A. Seiger and I. Stomberg, in: S. Federoff and L. Hertz (Eds.), Advances in Cellular Neurobiology, Academic Press, New York, NY, 1983, pp. 401-442.
35. C. Backman, P.T. Biddle, T. Ebendal, P.M. Friden, G.A. Gerhardt, M.A. Henry, L. Mackerlova, S. Soderstrom, I. Stromberg, L. Walus, B.J. Hoffer and A-C. Granholm, Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo, Exp. Neurol. 132 (1995) 1-15.
36. D.M. Frim, J. Simpson, T.A. Uhler, M.P. Short, S.R. Bossi, X.O. Breakfield and O. Isacson, Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF, J. Neurosci. Res. 35 (1993) 452-458.
37. L. Aloe, Intracerebral pretreatment with nerve growth factor prevents irreversible brain lesions in neonatal rats injected with ibotenic acid, Biotechnology 5 (1987) 1085-1086.
38. S.W. Davies and K. Beardsall, Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurons, Neurosci. Lett. 140 (1992) 161-164.
39. J.M. Schumacher, M.P. Short, B.T. Hyman, X.O. Breakfield and O. Isacson, Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids, Neuroscience 3 (1991) 561-570.
40. J.H. Kordower, V. Charles, R. Bayer, R.T. Bartus, S. Putney, L.R. Walus and P.M. Friden, Intravenous administration of a transferrin receptor-antibody conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington's disease, Proc. Natl. Acad. Sci. USA 91 (1994) 9077-9080.
41. T.L. Steininger, B.H. Wainer, R. Klein, M. Barbacid and H.C. Palfrey, High-affinity nerve growth factor receptor (trk) immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain, Brain Res. 612 (1993) 330-335.
42. J.H. Kordower, E.Y. Chen, J.R. Sladek Jr. and E.J. Mufson, trk immunoreactivity in the monkey central nervous system: forebrain, J. Comp. Neurol. 349 (1994) 20-35.
43. U. Bickel, T. Yoshikawa, E.M. Landaw, K.F. Faull and W.M. Pardridge, Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery, Proc. Natl. Acad. Sci. USA 90 (1992) 2618-2622.
44. S. White, R. Taetle, P.A. Seligman, M. Rutherford and I.S. Trowbridge, Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects, Cancer Res. 50 (1990) 6295-6301.
45. L.R. Walus, W.M. Pardridge, R.M. Starzyk and P.M. Friden, Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier following conjugation to anti-transferrin receptor antibodies, J. Pharmacol. Exp. Ther. 277 (1995) 1067-1075.